GH Research PLC (GHRS): Price and Financial Metrics


GH Research PLC (GHRS): $9.59

0.46 (+5.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GHRS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GHRS Stock Price Chart Interactive Chart >

Price chart for GHRS

GHRS Price/Volume Stats

Current price $9.59 52-week high $30.43
Prev. close $9.13 52-week low $8.72
Day low $8.94 Volume 118,600
Day high $9.75 Avg. volume 96,776
50-day MA $15.07 Dividend yield N/A
200-day MA $19.05 Market Cap 484.50M

GH Research PLC (GHRS) Company Bio


GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.


GHRS Latest News Stream


Event/Time News Detail
Loading, please wait...

GHRS Latest Social Stream


Loading social stream, please wait...

View Full GHRS Social Stream

Latest GHRS News From Around the Web

Below are the latest news stories about GH Research PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business. Third Quarter 2021 Financial Results Cash position Cash was $280.7 million as of September 30, 2021, compared to $5.9 million as of December 31, 2020. Research and development e

Yahoo | December 6, 2021

GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression

Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change from baseline in MADRS at day 7 after dosing was -24.4 points (-76%) (p<0.0001) GH001 was well tolerated and no serious adverse events were reported In addition, we announce positive preliminary safety results from a Phase 1 clinical pharmacology trial of GH001 in 46 healthy volunteers with 30-day follow

Yahoo | December 6, 2021

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

Yahoo | October 27, 2021

We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | September 25, 2021

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. Business Updates Corporate Updates In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issu

Yahoo | September 23, 2021

Read More 'GHRS' Stories Here

GHRS Price Returns

1-mo -35.16%
3-mo -40.03%
6-mo -61.14%
1-year N/A
3-year N/A
5-year N/A
YTD -58.89%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4806 seconds.